EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Final Analysis of the BRUIN Phase 1/2 Study Assessing the Safety and Efficacy of Pirtobrutinib Monotherapy in Patients With MCL

Michael L Wang iD, Jonathon B Cohen, Nirav N Shah iD, Wojciech Jurczak iD, Pier Luigi Zinzani iD, Chan Y Cheah iD, Chaitra S Ujjani iD, Youngil Koh iD, Won Seog Kim, Sunita D Nasta iD, Ian Flinn, Benoit Tessoulin iD und 25 weitere

American Journal of Hematology · 04.11.2026

DOI: 10.1002/ajh.70533 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 04.11.2026. Verfasst von Michael L Wang und 36 weiteren Autor:innen. Beteiligte Einrichtung: The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pirtobrutinib, a highly selective, non‐covalent Bruton tyrosine kinase inhibitor (BTKi) previously demonstrated durable efficacy and tolerable safety following covalent (c) BTKi therapy in heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL). Here, we report final results from the global Phase 1/2 BRUIN trial evaluating pirtobrutinib in patients with R/R MCL, with and without prior cBTKi exposure. Endpoints included overall response rate (ORR), duration of response (DOR), progression‐free survival (PFS), overall survival (OS), and safety. BRUIN enrolled 166 patients with R/R MCL (data cutoff: 27Jan2025). In the cBTKi‐exposed cohort ( n = 152), median study follow‐up time was 16.1 months (range, 0.5–69.6). The ORR was 49.3% (95% CI, 41.1–57.6). Median DOR was 21.6 months (95% CI, 9.2–27.2). Median PFS was 5.6 months (95% CI, 5.3–9.2; 36‐month rate, 19.9%). Median OS was 23.9 months (95% CI, 17.3–51.5; 36‐month rate, 43.2%). In the cBTKi‐naïve cohort ( n = 14), median study follow‐up time was 44.5 months (range, 1.6–67.1). The ORR was 85.7% (95% CI, 57.2–98.2). Median DOR was 42.7 months (95% CI, 25.8–not estimable [NE]). Median PFS was 44.6 months (95% CI, 16.7–NE; 36‐month rate, 58.7%). Median OS was NE (36‐month rate, 76.2%). The most frequent any‐grade treatment‐emergent adverse events (TEAEs) were infections (44.0%), fatigue (31.9%), and diarrhea (22.9%); the most frequent grade ≥ 3 TEAEs were infections (21.1%) and neutropenia (15.1%). Grade ≥ 3 hemorrhage (3.0%) and any‐grade atrial fibrillation/flutter (3.6%) were infrequent. With extended follow‐up, pirtobrutinib continued to demonstrate efficacy and favorable safety in cBTKi‐exposed and ‐naïve R/R MCL. Trial Registration: ClinicalTrials.gov identifier: NCT03740529

Schlagwörter

Stichwörter der Autor:innen

Bruton tyrosine kinase inhibitormantle cell lymphomanon‐covalent BTKipirtobrutinib

Autor:innen und Institutionen

  • The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
  • Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • Maria Skłodowska-Curie National Research Institute of Oncology, Krakow, Poland.
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", and Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy.
  • Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.

ORCID-Profile: Michael L Wang, Nirav N Shah, Wojciech Jurczak, Pier Luigi Zinzani, Chan Y Cheah, Chaitra S Ujjani, Youngil Koh, Sunita D Nasta, Benoit Tessoulin, Shuo Ma, Alvaro J Alencar, David J Lewis, Jennifer A Woyach, Yucai Wang, Joanna M Rhodes, Constantine S Tam, John F Seymour, Hirokazu Nagai, Julie M Vose, Bita Fakhri, Marc S Hoffmann, Andrew D Zelenetz, Talha Munir, Lindsey E Roeker, Toby A Eyre

Förderung

  • Eli Lilly and Company

Zitieren

APA

Wang, M. L., Cohen, J. B., Shah, N. N., Jurczak, W., Zinzani, P. L., Cheah, C. Y., Ujjani, C. S., Koh, Y., Kim, W. S., Nasta, S. D., Flinn, I., Tessoulin, B., Ma, S., Alencar, A. J., Lewis, D. J., Woyach, J. A., Maddocks, K. J., Patel, K., Wang, Y., …, & Eyre, T. A. (2026). Final Analysis of the BRUIN Phase 1/2 Study Assessing the Safety and Efficacy of Pirtobrutinib Monotherapy in Patients With MCL. American Journal of Hematology. https://doi.org/10.1002/ajh.70533

Vancouver

Wang ML, Cohen JB, Shah NN, Jurczak W, Zinzani PL, Cheah CY, et al. Final Analysis of the BRUIN Phase 1/2 Study Assessing the Safety and Efficacy of Pirtobrutinib Monotherapy in Patients With MCL. American Journal of Hematology. 2026. doi:10.1002/ajh.70533

BibTeX
@article{Wang2026,
  author = {Wang, Michael L and Cohen, Jonathon B and Shah, Nirav N and Jurczak, Wojciech and Zinzani, Pier Luigi and Cheah, Chan Y and Ujjani, Chaitra S and Koh, Youngil and Kim, Won Seog and Nasta, Sunita D and Flinn, Ian and Tessoulin, Benoit and Ma, Shuo and Alencar, Alvaro J and Lewis, David J and Woyach, Jennifer A and Maddocks, Kami J and Patel, Krish and Wang, Yucai and Rhodes, Joanna M and Tam, Constantine S and Seymour, John F and Nagai, Hirokazu and Vose, Julie M and Fakhri, Bita and Hoffmann, Marc S and Hernandez-Ilizaliturri, Francisco and Zelenetz, Andrew D and Kumar, Anita and Munir, Talha and Tsai, Donald E and Abada, Paolo and Balbas, Minna and Li, Jian and Wang, Denise and Roeker, Lindsey E and Eyre, Toby A},
  title = {Final Analysis of the BRUIN Phase 1/2 Study Assessing the Safety and Efficacy of Pirtobrutinib Monotherapy in Patients With MCL},
  journal = {American Journal of Hematology},
  year = {2026},
  doi = {10.1002/ajh.70533}
}
Kostenlos starten →